GEP201706769B - Composition of tiacumicin compounds - Google Patents

Composition of tiacumicin compounds

Info

Publication number
GEP201706769B
GEP201706769B GEAP201413898A GEAP2014013898A GEP201706769B GE P201706769 B GEP201706769 B GE P201706769B GE AP201413898 A GEAP201413898 A GE AP201413898A GE AP2014013898 A GEAP2014013898 A GE AP2014013898A GE P201706769 B GEP201706769 B GE P201706769B
Authority
GE
Georgia
Prior art keywords
composition
tiacumicin compounds
compounds
tiacumicin
carrageenan
Prior art date
Application number
GEAP201413898A
Other languages
English (en)
Inventor
Yoshiyuki Murakami
Hikaru Saito
Original Assignee
Astellas Pharma Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47563169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP201706769(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Europe Ltd filed Critical Astellas Pharma Europe Ltd
Publication of GEP201706769B publication Critical patent/GEP201706769B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GEAP201413898A 2013-01-15 2014-01-14 Composition of tiacumicin compounds GEP201706769B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13075002 2013-01-15

Publications (1)

Publication Number Publication Date
GEP201706769B true GEP201706769B (en) 2017-11-10

Family

ID=47563169

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201413898A GEP201706769B (en) 2013-01-15 2014-01-14 Composition of tiacumicin compounds

Country Status (28)

Country Link
US (1) US9808530B2 (enExample)
EP (1) EP2945613B1 (enExample)
JP (1) JP6338598B2 (enExample)
KR (1) KR102181474B1 (enExample)
CN (1) CN105120840B (enExample)
AR (1) AR094495A1 (enExample)
AU (1) AU2014207083B2 (enExample)
CA (1) CA2904808A1 (enExample)
CY (1) CY1121459T1 (enExample)
DK (1) DK2945613T3 (enExample)
EA (1) EA030049B1 (enExample)
ES (1) ES2705238T3 (enExample)
GE (1) GEP201706769B (enExample)
HR (1) HRP20182110T1 (enExample)
HU (1) HUE041421T2 (enExample)
IL (1) IL239899A0 (enExample)
JO (1) JO3464B1 (enExample)
LT (1) LT2945613T (enExample)
MD (1) MD4588C1 (enExample)
NZ (1) NZ710875A (enExample)
PL (1) PL2945613T3 (enExample)
PT (1) PT2945613T (enExample)
RS (1) RS58119B1 (enExample)
SI (1) SI2945613T1 (enExample)
TW (1) TWI646962B (enExample)
UA (1) UA117004C2 (enExample)
WO (1) WO2014111254A1 (enExample)
ZA (1) ZA201505048B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3139932T3 (en) 2014-05-09 2018-11-12 Astellas Pharma Europe Ltd The treatment regimen for thiacumicin compound
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物
CN116715678B (zh) * 2023-06-12 2025-09-30 中国科学院成都生物研究所 一种吲哚糖碳苷类大环化合物及其制备方法与应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3000792A (en) 1957-05-21 1961-09-19 Merck & Co Inc Antibiotic adsorption process
GB1458512A (en) 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4632902A (en) 1981-08-20 1986-12-30 Becton, Dickinson And Company Method for detecting biological activity in a body fluid
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
CA2050121C (en) 1991-03-04 2005-04-19 Glen A. Carey Automated analyzer
US5583115A (en) 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US5767096A (en) 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
CN100344627C (zh) 1996-11-18 2007-10-24 生物技术研究有限公司(Gbf) 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用
JP2000072760A (ja) 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
ATE309369T1 (de) 2000-04-28 2005-11-15 Kosan Biosciences Inc Heterologe herstellung von polyketiden
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
WO2004014295A2 (en) 2002-07-29 2004-02-19 Optimer Pharmaceuticals, Inc. Tiacumicin production
WO2006085838A1 (en) 2005-01-31 2006-08-17 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US20070105791A1 (en) 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
CA2510465A1 (en) 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
WO2005009474A1 (ja) 2003-07-24 2005-02-03 Shionogi & Co., Ltd. 難水溶性薬物を含むドライシロップ剤
JP3881640B2 (ja) 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
PL2070530T3 (pl) 2004-05-14 2016-06-30 Merck Sharp & Dohme Leczenie chorób związanych ze stosowaniem antybiotyków
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
US20110104267A1 (en) * 2005-04-25 2011-05-05 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
EP1940417A4 (en) 2005-10-21 2010-07-07 Optimer Pharmaceuticals Inc METHOD FOR TREATING DIARRHOE IN CONNECTION WITH CLOSTRIDIUM DIFFICILE
US20080176927A1 (en) 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
ZA200905337B (en) 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
US8999395B2 (en) 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JP5608880B2 (ja) * 2010-02-09 2014-10-22 林兼産業株式会社 嚥下困難者用高栄養ゼリー食品
CN102030791B (zh) 2010-10-28 2013-01-23 中国科学院南海海洋研究所 四种台勾霉素类化合物及其制备方法和在制备抗菌药物中的应用
CN102115757B (zh) 2010-12-14 2015-10-28 中国科学院南海海洋研究所 台勾霉素的生物合成基因簇及其应用

Also Published As

Publication number Publication date
HUE041421T2 (hu) 2019-05-28
CA2904808A1 (en) 2014-07-24
PT2945613T (pt) 2019-01-17
TW201440775A (zh) 2014-11-01
CY1121459T1 (el) 2020-05-29
HRP20182110T1 (hr) 2019-02-22
MD20150070A2 (ro) 2016-01-31
EP2945613B1 (en) 2018-10-10
UA117004C2 (uk) 2018-06-11
CN105120840B (zh) 2019-03-22
KR20150114498A (ko) 2015-10-12
US20160045603A1 (en) 2016-02-18
EP2945613A1 (en) 2015-11-25
MD4588B1 (ro) 2018-08-31
ZA201505048B (en) 2020-05-27
JP2016505026A (ja) 2016-02-18
KR102181474B1 (ko) 2020-11-23
AR094495A1 (es) 2015-08-05
US9808530B2 (en) 2017-11-07
RS58119B1 (sr) 2019-02-28
PL2945613T3 (pl) 2019-05-31
ES2705238T3 (es) 2019-03-22
TWI646962B (zh) 2019-01-11
EA030049B1 (ru) 2018-06-29
AU2014207083A1 (en) 2015-08-27
DK2945613T3 (en) 2019-01-14
EA201591226A1 (ru) 2016-01-29
MD4588C1 (ro) 2019-03-31
NZ710875A (en) 2019-10-25
WO2014111254A1 (en) 2014-07-24
IL239899A0 (en) 2015-08-31
JP6338598B2 (ja) 2018-06-06
SI2945613T1 (sl) 2019-02-28
JO3464B1 (ar) 2020-07-05
AU2014207083B2 (en) 2018-03-29
LT2945613T (lt) 2019-01-10
CN105120840A (zh) 2015-12-02

Similar Documents

Publication Publication Date Title
ZA201507627B (en) P2x7 modulators
MX2019008212A (es) Estructuras fibrosas que comprenden particulas y metodos para fabricarlas.
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX2015013163A (es) Complejos multiespecificos multivalente y monovalentes y sus usos.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX2016008448A (es) Conjugados de var2csa-farmaco.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX352563B (es) Composiciones para el cuidado oral que contienen carbonato de calcio y silice.
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
MX2018002061A (es) Soluciones de glicosidos de esteviol.
MY161601A (en) Films and compositions comprising the same
PH12013501311A1 (en) Polymer systems
IN2014MU00455A (enExample)
MX358132B (es) Solucion de trombina y metodos de uso de esta.
MX336369B (es) Uso de acido elagico como agentes anticaspa.
MX2016003207A (es) Composiciones que comprenden colina y derivados de esta, usos de las composiciones y procesos para su preparacion.
MX2015016603A (es) Composiciones de corticosteroides.
GEP201706769B (en) Composition of tiacumicin compounds
MX2015015537A (es) Formulacion de pastillas de nicotina.
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
GEP201606586B (en) Pediatric oral liquid compositions containing nepadutant
MX380670B (es) Complejo de quitina-glucano, su preparacion y usos.
IN2015DN02660A (enExample)
MX2016001694A (es) Formulacion de vacuna de sacarido.